换一批Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports.
第一作者：
Eman A,Alghamdi
第一单位：
Saudi Food and Drug Authority, Riyadh, Saudi Arabia.
作者：
关键词
ACS, Acute Coronary Syndrome’ADRs, Adverse Drug ReactionsATE, Arterial ThromboembolismAcute coronary syndromeCheckpoints inhibitorsDVT, Deep Vein Thrombosis’Deep vein thrombosisIC, Information ComponentICIs, Immune Checkpoint InhibitorsICSRs, Individual Case Safety ReportsIQR, Interquartile RangeLMWH, Low-Molecular-Weight HeparinMI, Myocardial InfarctionMedDRA, Medical Dictionary For Regulatory ActivitiesPD-1, Programmed Cell Death-1PD-L1, Programmed Cell Death Ligand 1PE, Pulmonary Embolism’PT, Preferred TermPulmonary embolismRR, Risk RatioTTO, Time To OnsetUFH, Unfractionated HeparinUMC, Uppsala Monitoring CentreVTE, Venous ThromboembolismVigiBaseWHO, World Health OrganizationirAEs, Immune-Related Adverse Events
DOI
10.1016/j.jsps.2022.06.010
PMID
36164566
发布时间
2022-09-28
- 浏览0
Saudi pharmaceutical journal
2022年30卷8期
1193-1199页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
